Life science research and diagnostics solutions provider Bruker Corporation (Nasdaq:BRKR) announced on Wednesday that it has acquired a majority stake in RECIPE Chemicals + Instruments GmbH, a Munich-based developer of mass spectrometry-based diagnostic assay kits.

RECIPE is a European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC and ICP-MS assays.

With more than four decades of experience and 2024 revenues exceeding USD15m, RECIPE will continue operations under managing director Dr Gernot Wolfram. The company employs over 60 people and is recognised for its ClinMASS kits, which support both Bruker and third-party mass spectrometry platforms.

This investment strengthens Bruker's clinical diagnostic portfolio, enabling integration of RECIPE's assays with Bruker's EVOQ liquid chromatography triple-quadrupole mass spectrometers. The companies are also launching the chromatography-free ClinDART platform for high-throughput drug monitoring.

ClinDART, designed for Bruker's EVOQ-DART TQ+ systems, offers rapid, cost-efficient testing without sacrificing analytical sensitivity or precision. The platform supports multiple-reaction monitoring and significantly reduces solvent use, boosting both sustainability and laboratory efficiency.